Tyrosine receptor kinase B is a drug target in astrocytomas.

导出 LinkOut

翻译打印收藏纠错

作者： Jing,Ni ^[1] ; Shaozhen,Xie ^[1] ; Shakti H,Ramkissoon ^[1] ; Victor,Luu ^[1] ; Yu,Sun ^[1] ; Pratiti,Bandopadhayay ^[1] ; Rameen,Beroukhim ^[1] ; Thomas M,Roberts ^[1] ; Charles D,Stiles ^[1] ; Rosalind A,Segal ^[1] ; Keith L,Ligon ^[1] ; William C,Hahn ^[1] ; Jean J,Zhao ^[2]

作者单位： Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (J.N., S.X., V.L., Y.S., P.B., R.B., T.M.R., C.D.S., R.A.S., J.J.Z.); Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts (J.N., S.X., V.L., T.M.R., J.J.Z.); Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (S.H.R., R.B., K.L.L., W.C.H.); Broad Institute, Boston, Massachusetts (P.B., R.B., W.C.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., K.L.L.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.). ^[1] Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts (J.N., S.X., V.L., Y.S., P.B., R.B., T.M.R., C.D.S., R.A.S., J.J.Z.); Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts (J.N., S.X., V.L., T.M.R., J.J.Z.); Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts (S.H.R., R.B., K.L.L., W.C.H.); Broad Institute, Boston, Massachusetts (P.B., R.B., W.C.H.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (S.H.R., K.L.L.); Department of Pathology, Boston Children's Hospital, Boston, Massachusetts (K.L.L.) jean_zhao@dfci.harvard.edu. ^[2]

关键词 NTRK2 CCL2 QKI-NTRK2 STAT3 astrocytoma